The REDUCE-AMI trial found that long-term beta-blocker therapy does not reduce mortality risk in acute myocardial infarction patients with preserved left ventricular ejection fraction compared to no beta-blocker treatment.
REDUCE-AMI concluded beta-blockers show no significant benefit following myocardial infarction among patients with normal left ventricular ejection fraction